Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Summary
This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial(IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Official title: A Single Arm, Phase II Clinical Study of Chemoradiationtherapy Combined With QL1706 (Anti-CTLA-4 and PD-1 Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2022-08-01
Completion Date
2025-09
Last Updated
2024-05-21
Healthy Volunteers
No
Conditions
Interventions
QL1706
QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
Locations (1)
Tianjin cancer hospital
Tianjin, Tianjin Municipality, China